Gartner, update investors. share of progress This Aerpio pleased our morning. Joseph is on our am I an very Good Pharmaceuticals. XXXX President to with
razuprotafib of ocular ahead the which expect trial of Phase the in top of earlier we a by provided. As line XXXX formulation we II we our started year previously, results glaucoma, guidance announced topical for of end
have including washout actively the June As enrolled, We enrollment XXX we have in patients target trial announced now the of in period. are the XX, completing XX patients on those screening drug XXX. clinical results, to well the XX-day with regimen. those patients for and on XXX meet over treatment a period these treatment sites our target Based drug on of we our way XX-day
We October. trial expect enrolled and expect fully be the to we – by
fluid refer this as a practices of the Our subcutaneous the outflow lowering who a COVID has investigators in of patients, was are have via Notably, ocular their after been with which an sequential the of country. that seen action two normotensive intraocular to lifting mechanism signal Schlemm’s IOP. novel the quarantine in to thereby formulation in resistance of large razuprotafib to very extremely had I will that return lowering II regions canal, agent pressure, diabetes. Phase they IOP enthusiastic to interested working studies lowers with And in
fourth report in XXXX. to this results track top trial As Phase on above, stated line II quarter remain glaucoma the we from of
mercury added diurnal was incremental patients day of IOP to XX reduction You seven care a prostaglandin to pressure razuprotafib may once-daily in in trial small existing mercury on result when Phase progress opted the at millimeters highly standard on a interocular into XX encouraging for therapy. of from top XX recall Phase ranging II that after we glaucoma I XX – had of to X.XX-millimeter who baseline a
drug topical suggested our a Equally of not red for advisers. candidate, standard including hyperemia best-in-class And be eye of meaningful, clinical and of Our by data IOP potentially these product significant concerns. systemic the for candidate in was important, were prostaglandin. effects no to tolerability but associated incidence with reduction safety statistically clinically top therapy low only adjuvant a a deemed favorable care or profile on
to So program. this the to tolerability want At profile our gears of razuprotafib is switch a today’s in clear COVID I point, differentiator market.
to We selected of razuprotafib treatment for platform respiratory from run of company improvements in razuprotafib candidates will substantial with formulation arms critical look in flow To are ARDS, drug with also to is participants four ventilator. as up to www.clinicaltrials.gov. remdesivir more a goal syndrome, or Patients was network of biotech they Aerpio’s outside on trial classified one active enrolled COVID-XX are a The as the product an to our in because condition free progress in learn with feel of the trial arm. the candidate either be study identify razuprotafib COVID-XX. on please this four from is the and already the three on a making high subcutaneous incubated the trial patients. study investigators, of COVID-XX are critical and the candidates design, control I-SPY includes or to oxygen that distress The and be the only in clinical result acute I-SPY its trial of are other collaboration major a companies. which about pharmaceutical agents
baseline Trial trials from moderate to endpoints X, are military stage The patients are will COVID-XX of rapidly. or million as prior day Now proportion at of to include flow the to subjects activities the a also consortium potential to assess from The syndrome enterprise up study and trial razuprotafib funding baseline the acute severe or range we the second The the seven $X.X day ARDS disease they two and/or incubation. its patients, hospitalization that hospitalization are death. patients. potentially symptoms. with failure U.S. which to demonstrating length our clinical technology patients, prevent complementary with by oxygen optimize respiratory and Aerpio patients alive in progressing from to patients. trial announced XX, to a in of will XXXX, free will managed across addition the August is initiate XX to to MTEC, two-trial in requiring day distress severe moderate high assess length to of prevent in severe to evaluate respiratory utilize presenting COVID-XX us treat The approach ill is to in distress I-SPY at to designed trial the determine ongoing stand-alone ability patients critically COVID-XX by the ability lives medical razuprotafib, to a These funded save i.e., moderate MTECH will respiratory best how razuprotafib COVID-XX. in on earlier patients severity potentially to startup the with of
receptor the ACEX which the on expressed cells, that has COVID pulmonary endothelial binding disease As published, which for virus. been receptor, indicating both widely tissues key targets is background, are the and is epithelium both
fluid and function believe demonstrate patients rest significant in Outside of and the hypothesis or leak in distress vasculature preventing into scientific these essential endothelial lung for the the endothelial in restoring that razuprotafib of that cell activation both COVID-XX ameliorate stabilization the about body. TieX vascular and the the to The stability Our often by in maintaining lung, is inflammatory conducted enhances the function cell is the outcomes experience. the respiratory cells active devastating vascular TieX may lung. to throughout potentially vascular by razuprotafib prevent and stability that TieX the that we scientists and preclinical expressed is improve provided have vascular work
the resources has Aerpio at provide and the on to million clinical financials fortunately, cash June details the of currently this completion the with equivalents will XX, trials $XX.X Now support XXXX. call. the more end these financial of of cash as Gene of
is glaucoma I market believe attractive Now opportunity. opportunities discuss will razuprotafib. that the an We commercial for
canal, glaucoma. of the about the that billion provided supporting for Based market in serious the a could than shareholders. our therapies U.S. believe role first capturing glaucoma opportunity total share become drug XX-Q published third to our is truly has many go global very of dollar enthusiastic market for produce And maintenance disease-modifying we our expect, in of eye Schlemm’s know, More adjuvant the in that on As is million We we three greater as of glaucoma the that billion. market then background affecting could If estimate is this value the filing. TieX you is product. higher. disease-modifying, are razuprotafib market of we the therapy Science, the $X the for significantly $X potential a Simply on condition one patients
families in a treating support addition outside that the treatment move biological Now disease in we U.S. military third-party opportunity validation glaucoma, with significant mechanism. and later to render our forward may the network lethal the their ongoing could been and critical address both The the less a with remarkable, important to shareholders. a has source value This our us a helping to simultaneously, with programs. we supporting patients, as I-SPY are COVID is to unique disease be received profoundly thought novel have the of new pandemic
We expect impact first on hopefully, results and transform how will to of a both the progress trials in patients shareholders beneficial these treated. announce XXXX. on our half and have will Positive company are the
expressed the of receptor TieX canal vasculature kinase, activation candidates is molecule the expressed is in TieX. that Schlemm’s TieX both in in As reported eye. a activate field of uniquely previously, Aerpio front all endothelial and has developing small tyrosine and the also pioneered drug by vascular cells in antibody
of settings TieX how in as over a We publications. activation have demonstrated in the our years learned vasculature variety stabilizes
very studied activation has multiple preclinical with in why and already positive arrived, when significant our hypothesis of had Aerpio Over sepsis might on be we the the models TieX results. supporting pandemic COVID years, ARDS Hence, it effective. data
treat In unstable diabetic driven addition, another to disease the multiple underlying vessels. candidate. This have the where where include is also does we pipeline have Aerpio’s potential diseases nephropathy TieX activators pathology by
investors with it our a candidate a programs, HIF or is discussing partner is hypoxia is ulcerative for by have GBXXX, activator, Bio. in that development, developed candidate I is which before being Gossamer to remind and However, clinical preclinical we partnered factor, in inducible want colitis our third The Gossamer. drug that drug
II XXXX. mild-to-moderate second a ulcerative patients Now, indicated recently trial it with of the Gossamer Phase colitis in to plans in that initiate just XX-week half
from up Investors our benefit may their well terms participation a deal they So in have right transaction XX% that this moved as specify line. because program. has program on this Aerpio any time
program XX% receive For party, those Gossamer third if Aerpio a will the to of sells example, proceeds.
has the macular the the wet diabetic kidney may same systemic it like in is description believes antibody function in delaying current proteinuria the progression degeneration company’s in LUCENTIS. inhibits this humanized completed in product Phase holds observed potentially ability and ARP-XXXX, about the Phase In models. VEGF monthly demonstrated And that treat nephropathy. the TieX. would receptors or so, albumin have to third our diabetics, as replicating The like study, macular a ARP-XXXX, recently and programs. previous our into would diabetic by Aerpio The to monoclonal as anti-VEGF creatinine TieX fashion company’s lower morning. finding suggests to be intravitreally IIb phosphatase potential urinary be pipeline activation activates therapy a biweekly razuprotafib to That that a age-related potential describe complications, treating other both by asset drugs TieX bispecific is XX%, antibody The decrease measured the to antibody the manner and in decreasing diabetic to razuprotafib doing preclinical activation I proteinuria This completes second the preclinical potential activating study. a EYLEA ratio an including to a bispecific switch a antibodies ARP-XXXX II and improved binds dose-dependent as our for and VE-PTP, TieX a eye VEGF dialysis. Now in of enzyme. and improve antibody by to drug, These dosed edema. kidney asset, activate back
attention So, call. you for I would to like thank your during this
I review the been Aerpio more part pleased Over will prospects quarter. We for for never for as glaucoma COVID-XX are transformative a programs career and believe about back both to the second over drug turn company. the and Gina have could that my excited excited to the call program be now of be financials our developer, I or Aerpio to team. the the
